» Articles » PMID: 22177734

Cancer Invasion and Resistance: Interconnected Processes of Disease Progression and Therapy Failure

Overview
Journal Trends Mol Med
Date 2011 Dec 20
PMID 22177734
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer progression and outcome depend upon two key functions executed by tumor cells: the growth and survival capability leading to resistance to therapy and the invasion into host tissues resulting in local and metastatic dissemination. Although both processes are widely studied separately, the underlying cell-intrinsic and microenvironmentally controlled signaling pathways reveal substantial overlap in mechanism. Candidate signaling hubs that serve both tumor invasion and resistance include growth factor and chemokine signaling, integrin engagement, and components of the Ras/MAPKs, PI3K, and mTOR signaling pathways. In this review, we summarize these and other mechanisms controlled by the microenvironment that jointly support cancer cell survival and resistance, as well as the invasion machinery. We also discuss their interdependencies and the implications for therapeutic dual- or multi-pathway targeting.

Citing Articles

Cancer invasion and anaerobic bacteria: new insights into mechanisms.

Hurst R, Brewer D, Gihawi A, Wain J, Cooper C J Med Microbiol. 2024; 73(3).

PMID: 38535967 PMC: 10995961. DOI: 10.1099/jmm.0.001817.


Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer.

Uehara M, Domoto T, Takenaka S, Takeuchi O, Shimasaki T, Miyashita T Cancer Drug Resist. 2024; 7:4.

PMID: 38318525 PMC: 10838383. DOI: 10.20517/cdr.2023.84.


Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer.

Park J, Kang S, Kwon W, Jeong I, Kim T, Yu S Sci Rep. 2023; 13(1):22648.

PMID: 38114573 PMC: 10730520. DOI: 10.1038/s41598-023-49646-5.


Pan-cancer whole-genome comparison of primary and metastatic solid tumours.

Martinez-Jimenez F, Movasati A, Brunner S, Nguyen L, Priestley P, Cuppen E Nature. 2023; 618(7964):333-341.

PMID: 37165194 PMC: 10247378. DOI: 10.1038/s41586-023-06054-z.


Loss of EPS8 sensitizes non-small-cell lung carcinoma to chemotherapy-induced DNA damage.

Qiu Y, Xu B, Feng J, Wang C, Chen Y, He Y Cancer Gene Ther. 2023; 30(7):997-1006.

PMID: 36932195 DOI: 10.1038/s41417-023-00606-1.